You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Acceleration of Commercial Low-Rank Matrix Solver via SLATE

    SBC: IERUS TECHNOLOGIES, INC            Topic: 07a

    Performing accurate simulations of large- and multi-scale electromagnetics problems has far-reaching implications The same physics governs applications as diverse as rare earth content reduction in DC motor design; wireless propagation in dense urban environments and novel antenna design, both key issues in the pending 5G communications boom; electromagnetic sounding for subsurface exo-terrestrial ...

    STTR Phase I 2020 Department of Energy
  2. Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. A Continuous Low-Inventory Tritium Fuel Cycle for Fusion

    SBC: Cryogenic Applications F, Inc.            Topic: N/A

    A Continuous Low-Inventory Tritium Fuel Cycle for Fusion DOE Grant No. DE-FG02-98ER86075 Amount: $99,999 Small Business Cryogenic Applications F, Inc. 450 Bacon Springs Lane Clinton, TN 37716-5311 Dr. Christopher A. Foster, Principal Investigator Dr. Christopher A. Foster, Business Official (423) 435-5433 Research Institution Los Alamos National Laboratory MS C334 P.O. Box 1663 Los Alamos, NM ...

    STTR Phase I 1998 Department of Energy
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. A Mesh Free Framework for Mechanical Simulations of Microstructure Data Files

    SBC: CFD Research Corporation            Topic: 07a

    The Exascale Computing Project is tasked to develop the next generation of high performance computing systems capable of computing at 50 to 100 times faster than current HPC systems. Computing at this extreme-scale will significantly enhance the value of materials modeling and simulation to basic materials research and engineering In particular, computing at the extreme scale will enable a higher ...

    STTR Phase I 2019 Department of Energy
  9. A Multi-physics Analysis Capability for Engine Materials

    SBC: Sunergolab Inc.            Topic: 03b

    Computer-aided Engineering software that apply the Finite Element Method to perform a multi-physics analysis have received widespread acceptance for traditional macro-scale material systems. Challenges persist in the modeling of complex coupled processes in environmental/thermal barrier coatings (E/TBCs) used to protect substrate material against the corrosive environment in the hot section parts ...

    STTR Phase I 2019 Department of Energy
  10. An Advanced Biosensor for Molecular Interaction Studies

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government